VIPR1-AS1

Across TCGA pan-cancer cohorts, VIPR1-AS1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of VIPR1-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where VIPR1-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types VIPR1-AS1 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

THCA, LUSC, and LUAD are the cancer types where VIPR1-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in VIPR1-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	All	−0.094	<.001	10	view →
LUSC	Female	All	−1.106	<.001	8	view →
LUAD	Female	All	−0.713	<.001	7	view →
KIRP	Male	All	−0.061	<.001	7	view →
BRCA	Female	All	−0.340	<.001	6	view →
COAD	All	II,III,IV	−0.305	.005	5	view →
LIHC	Male	III,IV	−0.057	.003	5	view →
READ	Male	All	−0.973	.017	2	view →
PRAD	All	All	+0.278	.002	2	view →
UCEC	All	All	+0.084	.010	2	view →
KIRC	All	All	+0.021	.011	2	view →
ESCA	Female	All	−0.440	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

VIPR1-AS1–THCA

Open the THCA breakdown →